<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="640">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01703468</url>
  </required_header>
  <id_info>
    <org_study_id>OXCA-S600-PVFD-2</org_study_id>
    <nct_id>NCT01703468</nct_id>
  </id_info>
  <brief_title>Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions</brief_title>
  <official_title>A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roxane Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roxane Laboratories</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to prove the bioequivalence of Roxane Laboratories'
      Oxcarbazepine Suspension 600 mg under fed conditions
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>bioequivalence determined by statistical comparison Cmax</measure>
    <time_frame>10 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood sampling taken during specified time points to determine bioequivalence</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Seizures</condition>
  <arm_group>
    <arm_group_label>Oxcarbazepine then Trileptal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600 mg suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trileptal then Oxcarbazepine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600 mg suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxcarbazepine</intervention_name>
    <arm_group_label>Oxcarbazepine then Trileptal</arm_group_label>
    <arm_group_label>Trileptal then Oxcarbazepine</arm_group_label>
    <other_name>Trileptal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No clinically significant abnormal findings on the physical examination, medical
             history, or clinical laboratory results during screening

        Exclusion Criteria:

          -  Positive test for HIV, Hepatitis B, or Hepatitis C.

          -  Treatment with known enzyme altering drugs.

          -  History of allergic or adverse response to oxcarbazepine or any comparable or similar
             product.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia Zamora, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 17, 2014</lastchanged_date>
  <firstreceived_date>October 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carbamazepine</mesh_term>
    <mesh_term>Oxcarbazepine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
